Safety and efficacy of nemonoxacin versus levofloxacin in the treatment of community-acquired pneumonia: results of phase III, multicenter, randomized, double-blind, active-controlled, non-inferiority trial | CMAC

Safety and efficacy of nemonoxacin versus levofloxacin in the treatment of community-acquired pneumonia: results of phase III, multicenter, randomized, double-blind, active-controlled, non-inferiority trial

Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(4):341-353

​ Kozlov R.S., Dekhnich A.V., Zaitsev A.A., Nilk R.Ya., Samsonov M.Yu., Berezhanskiy B.V., Salazanov D.A.
10.36488/cmac.2018.4.341-353
nemonoxacin levofloxacin community-acquired pneumonia efficacy safety clinical trial
Section
Antimicrobials
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(4):341-353

Objective.

To evaluate the efficacy and safety of a step-down strategy from intravenous to oral nemonoxacin versus a step-down strategy from intravenous to oral levofloxacin in the treatment of patients with community-acquired pneumonia.

Materials and Methods.

This was a phase III randomized, controlled, double-blind, double-dummy, parallel groups (2 groups), multicenter trial to evaluate the efficacy and safety of intravenous and oral nemonoxacin at a daily dose of 500 mg versus levofloxacin (Tavanic®) at a daily dose of 500 mg in the treatment of adult patients with community-acquired pneumonia. A total of 342 patients from 25 sites were randomized with 171 patients in the control group and 171 patients in the study group.

Results.

A total of 169 patients in the nemonoxacin group and 166 patients in the levofloxacin group received at least one dose of the study drug and were clinically evaluable (mITT, modified intention-to-treat population). At the test-of-cure visit, the clinical cure rates were 93.5% and 87.3% in the nemonoxacin and levofloxacin groups, respectively (the difference in clinical success rates was 6.1% [95% CI: -0.7–13.0%]). The median time to switching to oral therapy was 4 days in both groups. Two (1.2%) and five (3.0%) patients out of 169 and 166 patients in the nemonoxacin and levofloxacin groups, respectively, required treatment with other antibiotics, the difference being insignificant (p = 0,259). The microbiological efficacy cannot be evaluated reliably due to an insignificant number of positive microbiological results. The incidence of drug-related adverse events (ADR) was 38.0% and 20.7% in the nemonoxacin and levofloxacin groups, respectively. After switching to oral treatment, the incidence of ADR was comparable between the study and control groups constituting 8.8% and 8.9%, respectively.

Conclusions.

Clinically, a step-down therapy with nemonoxacin at a dose of 500 mg once daily was noninferior compared with step-down therapy with levofloxacin at a dose of 500 mg once daily.

Roman S. Kozlov

Institute of Antimicrobial Chemotherapy, Smolensk State Medical University, Smolensk, Russia

Andrey V. Dekhnich

Institute of Antimicrobial Chemotherapy, Smolensk State Medical University, Smolensk, Russia

Zaitsev A.A.

Main Military Clinical Hospital named after N.N. Burdenko, Moscow, Russia

Nilk R.Ya.

City Hospital No. 38 named after N.A. Semashko, Saint Petersburg, Russia

Samsonov M.Yu.

R-Pharm JSC, Moscow, Russia

Berezhanskiy B.V.

R-Pharm JSC, Moscow, Russia

Salazanov D.A.

R-Pharm JSC, Moscow, Russia

  • 1. Статистические материалы Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека. Москва, 2018.
  • 2. Jackson M.L., Neuzil K.M., Thompson W.W., et al. The burden of community-acquired pneumonia in seniors: results of a populationbased study Clin Infect Dis. 2004;39:1642-1650.
  • 3. Welte T., Torres A., Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2010;67(1):71-79.
  • 4. Ramirez J.A., Wiemken T.L., Peyrani P., et al. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis. 2017;65(11):1806-1812.
  • 5. Torres A., Blasi F., Peetermans W.E., et al. The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review. Eur J Clin Microbiol Infect Dis. 2014;33(7):10651079.
  • 6. Johansson N., Kalin M., Tiveljung-Lindell A., et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis. 2010;50:202–209.
  • 7. Mandell L.M., Wunderink R.G, Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27-72.
  • 8. Rider A.C., Frazee B.W. Community-acquired pneumonia. Emerg Med Clin North Am. 2018;36(4):665-683.
  • 9. Kuzmenkov A.Yu, Trushin I.V, Avramenko A.A., et al. AMRmap: an online platform for monitoring antibiotic resistance. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2017;19(2):84-90. Russian.
  • 10. Adam H.J., Laing N.M., King C.R., et al. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. Antimicrob Agents Chemother. 2009;53:49154920.
  • 11. Li C.R., Li Y., Li G.Q., et al. In vivo antibacterial activity of nemonoxacin, a novel non-fluorinated quinolone. J Antimicrob Chemother. 2010;65:2411-2415.
  • 12. Lauderdale T.L., Shiau Y.R., Lai J.F., Chen H.C., King C.H. Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates. Antimicrob Agents Chemother. 2010;54:1338-1342.
  • 13. Chen Y.H., Liu C.Y., Ko W.C., et al. Trends in the susceptibility of methicillin-resistant Staphylococcus aureus to nine antimicrobial agents, including ceftobiprole, nemonoxacin, and tyrothricin: results from the tigecycline in vitro surveillance in Taiwan (TIST) study, 2006– 2010. Eur J Clin Microbiol Infect Dis. 2014;33:233-239.
  • 14. Chotikanatis K., Kohlhoff S.A., Hammerschlag M.R. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother. 2014;58:1800-1801.
  • 15. Kozlov R.S., Dekhnich A.V., Sukhorukova M.V., Edelstein M.V., Chernavin A., Samsonov M.Yu. In-vitro activity of nemonoxacin against Streptococcus pneumoniae and Haemophilus influenzae. Proceedings of the 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria; 22-25 April 2017. Abstract/ Poster EV0440.
  • 16. Yuan J., Mo B., Ma Z., et al. Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial. J Microbiol Immunol Infect. 2017:S1684-1182(17)30151-2.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared